Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
BARD1 CRISPR Activation Plasmid (h): sc-401212-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BARD1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- BARD1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by BARD1 CRISPR Activation Plasmid (h) and BARD1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the BARD1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BARD1 Antibody (E-11): sc-74559
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BARD1 CRISPR Activation Plasmid (h) | sc-401212-ACT | 20 µg | $397.00 |
BARD1 (BRCA1 associated RING domain 1) encodes a nuclear protein that heterodimerizes with BRCA1 to form an E3 ubiquitin ligase complex central to genome maintenance. This complex coordinates DNA double-strand break signaling and repair, supports replication fork stability, and contributes to cell-cycle checkpoint control through ubiquitin-dependent regulation of chromatin-associated substrates. BARD1 also participates in transcriptional regulation and apoptosis-related processes, linking DNA damage responses to broader cellular stress pathways. Altered BARD1 expression or function has been associated with defective homologous recombination, chromosomal instability, and cancer susceptibility phenotypes, making it a relevant target for mechanistic studies of tumor suppressor networks.
BARD1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous BARD1 expression without altering the underlying DNA sequence.
BARD1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the BARD1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the BARD1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous BARD1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native BARD1 locus and enabling the study of BARD1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of BARD1 pathway restoration in tumor cells with silenced or reduced BARD1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.